Cite
HARVARD Citation
Bayliss, J. et al. (2017). Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 66 (11), pp. 2013-2023. [Online].